Last updated: February 17, 2026
Overview of NDC 23155-0500
NDC 23155-0500 corresponds to Fasenra (benralizumab), a monoclonal antibody used for severe eosinophilic asthma and chronic obstructive pulmonary disease (COPD). Approved by the FDA in 2017, Fasenra has established itself within the biologic asthma treatment segment.
Market Size and Demand Dynamics
Asthma and COPD Market Context:
- The global asthma therapeutics market reached $14.4 billion in 2022, with biologic therapies accounting for approximately 20% of this figure.
- Severe eosinophilic asthma comprises about 10-15% of the adult asthma population, estimated at 25 million globally.[1]
- COPD affects approximately 200 million individuals worldwide.[2]
Fasenra's Market Penetration:
- As of 2022, Fasenra holds an estimated 25% share in biologic therapies for severe eosinophilic asthma, competing primarily with drugs such as Nucala (mepolizumab) and Cinqair (reslizumab).
- The primary markets are the U.S., Europe, and Japan, with growth prospects in emerging markets.
Growth Drivers:
- Rising prevalence of severe asthma and COPD.
- Increased adoption of antibody-based therapies due to their targeted mechanism.
- Expanded indications; developments ongoing for COPD approval in select regions.
Constraints:
- High treatment cost.
- Competition with alternative biologics with similar efficacy profiles.
- Reimbursement challenges.
Pricing Trends and Projections
Current Pricing Landscape
-
U.S. Price:
- Average list price per injection (100 mg): approximately $9,500.
- Typical dosing: 30 mg every 4 weeks after initial dosing.
- Annual cost per patient: roughly $35,000 to $40,000, depending on the dosing schedule.
-
European Price:
- Retail prices range from €6,000 to €8,000 per dose, translating to annual costs similar to U.S. figures.
Market Pricing Trends
- Price reductions in the U.S. for biologics have been modest, generally around 5-10% over two years.
- Payer negotiations and rebate agreements (often 20-30%) further lower net prices.
- Biosimilars are not currently available, maintaining high brand loyalty.
Price Projection Models for 2023–2028
Factors influencing future prices:
- Patent exclusivity extending until 2028 in key markets.
- Increasing utilization driven by expanded indications.
- Competitive pressure from biosimilar entry anticipated around 2028, potentially reducing prices by 15-25%.
| Year |
Estimated Average Wholesale Price (AWP) |
Notes |
| 2023 |
$9,500 per 100 mg injection |
Current market price |
| 2024 |
$9,025 – $9,500 |
Slight reduction due to negotiations |
| 2025 |
$8,775 – $9,425 |
Marginal price pressure, slow decline |
| 2026 |
$8,500 – $9,200 |
Approaching patent expiration, increased competition |
| 2027 |
$8,150 – $8,800 |
Anticipated biosimilar development baselines |
| 2028 |
$7,500 – $8,300 |
Potential biosimilar launch, price adjustments |
Note: These projections assume steady demand and lack significant regulatory or policy disruptions.
Competitive Landscape
- Nucala (mepolizumab): Broadly similar in price, with slightly different dosing.
- Cinqair (reslizumab): Similar annual costs but administered intravenously.
- Tezepelumab (pending approval): Offers alternative therapy with competitive pricing in pipeline.
Regulatory and Policy Impact
Expirations of patent exclusivity in 2028 open pathways for biosimilar competition, which historically leads to 15-25% price decreases.[3]
Reimbursement policies and payer strategies will shape actual transaction prices, often lower than list prices.
Key Takeaways
- The current market price for NDC 23155-0500 (Fasenra) is approximately $9,500 per 100 mg dose.
- The drug maintains a strong market position with limited competition, supporting stable pricing until biosimilar entry.
- By 2028, prices are expected to decline by 15-25% due to biosimilar competition.
- Market growth will be driven by increasing prevalence of severe eosinophilic asthma and COPD, especially in neglected markets.
- Reimbursement negotiations and policy developments may further influence actual net prices.
FAQs
Q1: How does Fasenra’s price compare with other biologics for asthma?
Fasenra's list price per dose is similar to Nucala, generally around $9,500, but actual net prices tend to be lower due to rebates and negotiations.
Q2: What factors could alter the price forecast?
Patent expirations, biosimilar development, regulatory changes, and reimbursement policy shifts.
Q3: When could biosimilars realistically enter the market?
Patent expiration expected in 2028, with biosimilars potentially launching in the subsequent 12-24 months.
Q4: How does demand influence future pricing?
Increased adoption, especially for expanded indications, sustains higher prices until biosimilar entry.
Q5: What is the primary market for Fasenra?
The U.S. accounts for most revenue, with Europe and Japan following suit.
Sources
- Global Data. "Asthma Market Outlook," 2022.
- WHO. "Global Burden of COPD," 2021.
- IMS Health. "Biosimilar Impact on Biologics," 2021.
